BRPI1011683A2 - derivado isoquinolina substituída - Google Patents

derivado isoquinolina substituída

Info

Publication number
BRPI1011683A2
BRPI1011683A2 BRPI1011683A BRPI1011683A BRPI1011683A2 BR PI1011683 A2 BRPI1011683 A2 BR PI1011683A2 BR PI1011683 A BRPI1011683 A BR PI1011683A BR PI1011683 A BRPI1011683 A BR PI1011683A BR PI1011683 A2 BRPI1011683 A2 BR PI1011683A2
Authority
BR
Brazil
Prior art keywords
isoquinoline derivative
substituted isoquinoline
substituted
derivative
isoquinoline
Prior art date
Application number
BRPI1011683A
Other languages
English (en)
Inventor
Hiroyoshi Hidaka
Kengo Sumi
Kouichi Takahashi
Ryohei Nakamura
Yoshihiro Inoue
Original Assignee
Western Therapeutics Inst Inc D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Western Therapeutics Inst Inc D filed Critical Western Therapeutics Inst Inc D
Publication of BRPI1011683A2 publication Critical patent/BRPI1011683A2/pt
Publication of BRPI1011683B1 publication Critical patent/BRPI1011683B1/pt
Publication of BRPI1011683B8 publication Critical patent/BRPI1011683B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
BRPI1011683A 2009-06-19 2010-06-18 derivados de isoquinolina substituída, suas composições farmacêuticas e seus usos BRPI1011683B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009146040 2009-06-19
JP2009-146040 2009-06-19
PCT/JP2010/004101 WO2010146881A1 (ja) 2009-06-19 2010-06-18 置換されたイソキノリン誘導体

Publications (3)

Publication Number Publication Date
BRPI1011683A2 true BRPI1011683A2 (pt) 2016-03-22
BRPI1011683B1 BRPI1011683B1 (pt) 2020-10-20
BRPI1011683B8 BRPI1011683B8 (pt) 2021-05-25

Family

ID=43356211

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011683A BRPI1011683B8 (pt) 2009-06-19 2010-06-18 derivados de isoquinolina substituída, suas composições farmacêuticas e seus usos

Country Status (19)

Country Link
US (1) US8951997B2 (pt)
EP (1) EP2444395B1 (pt)
JP (1) JP4915010B2 (pt)
KR (1) KR101732907B1 (pt)
CN (1) CN102448941B (pt)
AU (1) AU2010261206B2 (pt)
BR (1) BRPI1011683B8 (pt)
CA (1) CA2764124C (pt)
CY (1) CY1117157T1 (pt)
DK (1) DK2444395T3 (pt)
EA (1) EA019523B1 (pt)
ES (1) ES2560603T3 (pt)
HR (1) HRP20160096T1 (pt)
HU (1) HUE028684T2 (pt)
MX (1) MX2011013857A (pt)
NZ (1) NZ596615A (pt)
PL (1) PL2444395T3 (pt)
TW (1) TWI527798B (pt)
WO (1) WO2010146881A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
EP3828172A1 (en) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US8883792B2 (en) 2010-12-22 2014-11-11 D. Western Therapeutics Institute, Inc. Substituted isoquinoline derivative
JP2013035802A (ja) * 2011-08-10 2013-02-21 D Western Therapeutics Institute Inc 緑内障又は高眼圧症の予防又は治療剤
ES2852377T3 (es) 2013-03-15 2021-09-13 Aerie Pharmaceuticals Inc Sales dimesilato de 4-(3-amino-1-(isoquinolin-6-ilamino)-1-oxopropan-2-il)bencilo, sus combinaciones con prostaglandinas y el uso de las mismas en el tratamiento de trastornos oculares
JP5557408B1 (ja) * 2013-04-24 2014-07-23 国立大学法人九州大学 眼底疾患治療剤
CN105085478B (zh) * 2014-04-28 2019-04-12 南京明德新药研发股份有限公司 异喹啉磺胺衍生物及其药物组合物和制药用途
CN105906609A (zh) * 2016-05-19 2016-08-31 武昌理工学院 一种1,4-二氮杂环庚烷衍生物的制备方法
KR102568079B1 (ko) 2016-08-31 2023-08-17 에어리 파마슈티컬즈, 인코포레이티드 안과용 조성물
BR112019003557A2 (pt) 2016-08-31 2019-05-21 Jiangsu Hengrui Medicine Co., Ltd. derivados de oxopicolinamida, método de preparação dos mesmos e uso farmacêutico dos mesmos
US9840468B1 (en) 2016-12-30 2017-12-12 Aerie Pharmaceuticals, Inc. Methods for the preparation of 6-aminoisoquinoline
AU2018243687C1 (en) 2017-03-31 2020-12-24 Alcon Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CN109134433B (zh) * 2017-06-16 2021-05-25 成都先导药物开发股份有限公司 一种抑制rock的化合物及其应用
CN108929270B (zh) * 2018-08-15 2021-06-08 上海罕道医药科技有限公司 一种药物中间体双取代含氮杂环的胺类化合物的合成
CA3112391A1 (en) 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
KR102811620B1 (ko) * 2018-11-01 2025-05-22 가부시키가이샤 디. 웨스턴 세라퓨틱스 겡큐쇼 1,4-디아조칸 화합물 또는 이의 염
JP7792670B2 (ja) * 2018-12-18 2025-12-26 株式会社デ・ウエスタン・セラピテクス研究所 イソキノリンスルホニルクロリド酸付加塩及びその製造方法
AU2021331624A1 (en) * 2020-08-31 2023-05-04 Visus Therapeutics, Inc. Compounds and formulations for treating ophthalmic diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456757A (en) 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
JPS5993054A (ja) 1982-11-18 1984-05-29 Asahi Chem Ind Co Ltd イソキノリンスルホン酸アミド誘導体
US4678783B1 (en) 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
JPH0667926B2 (ja) 1985-11-12 1994-08-31 旭化成工業株式会社 環状のイソキノリンスルホンアミド誘導体
JPH0215067A (ja) 1988-07-04 1990-01-18 Hokuriku Seiyaku Co Ltd イソキノリンスルホンアミド誘導体
US5216150A (en) 1988-12-26 1993-06-01 Hiroyoshi Hidaka Derivatives of isoquinoline (and naphthalene) sulfonamides
US5245034A (en) 1988-12-26 1993-09-14 Kiroyoshi Hidaka Compound having vessel smooth muscle relaxation activity
JPH069402A (ja) 1991-05-15 1994-01-18 Hiroyoshi Hidaka 抗潰瘍剤
ES2205166T3 (es) 1996-02-02 2004-05-01 D. Western Therapeutics Institute Derivados de isoquinolina y medicamento.
EP1395257A1 (en) * 2001-06-12 2004-03-10 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
CA2556589A1 (en) * 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
US20050272723A1 (en) 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2006115247A1 (ja) 2005-04-25 2006-11-02 D. Western Therapeutics Institute, Inc. 高選択的Rhoキナーゼ阻害剤
WO2006115244A1 (ja) 2005-04-25 2006-11-02 D. Western Therapeutics Institute, Inc. 4-ブロモイソキノリン誘導体及びこれを含有する医薬
CA2621181C (en) 2005-08-30 2011-04-19 Asahi Kasei Pharma Corporation 5-isoquinolinesulfonamide compounds
US20080064681A1 (en) 2006-09-11 2008-03-13 Hiroyoshi Hidaka Therapeutic agent for treating glaucoma
PT2125744E (pt) 2006-12-27 2011-07-01 Sanofi Aventis Derivados de isoquinolona e isoquinolinona substituídos com cicloalquilamina
MX2009005964A (es) 2006-12-27 2009-06-15 Sanofi Aventis Derivados de isoquinolina sustituidos con cicloalquilamina.
AU2008220104B2 (en) 2007-02-28 2012-09-27 Asahi Kasei Pharma Corporation Sulfonamide derivative

Also Published As

Publication number Publication date
PL2444395T3 (pl) 2016-06-30
CN102448941B (zh) 2016-04-06
AU2010261206A1 (en) 2011-12-15
TW201100385A (en) 2011-01-01
KR101732907B1 (ko) 2017-05-08
EP2444395A4 (en) 2012-11-28
JP4915010B2 (ja) 2012-04-11
HUE028684T2 (en) 2016-12-28
HRP20160096T1 (hr) 2016-02-26
DK2444395T3 (en) 2016-03-14
CA2764124A1 (en) 2010-12-23
WO2010146881A1 (ja) 2010-12-23
BRPI1011683B1 (pt) 2020-10-20
EA201171328A1 (ru) 2012-05-30
EA019523B1 (ru) 2014-04-30
JPWO2010146881A1 (ja) 2012-12-06
CN102448941A (zh) 2012-05-09
EP2444395A1 (en) 2012-04-25
AU2010261206B2 (en) 2015-10-08
US8951997B2 (en) 2015-02-10
EP2444395B1 (en) 2016-01-06
US20120035159A1 (en) 2012-02-09
NZ596615A (en) 2013-07-26
KR20120069609A (ko) 2012-06-28
TWI527798B (zh) 2016-04-01
BRPI1011683B8 (pt) 2021-05-25
CY1117157T1 (el) 2017-04-05
ES2560603T3 (es) 2016-02-22
CA2764124C (en) 2016-12-13
MX2011013857A (es) 2012-01-30

Similar Documents

Publication Publication Date Title
BRPI1011683A2 (pt) derivado isoquinolina substituída
EP2433940A4 (en) SPIROIMIDAZOLONDERIVAT
BRPI1008774A2 (pt) espiroamida substituída
ECSP12011999A (es) Derivados benzamida sustituidos
EP2404918A4 (en) pyridine
BRPI1013246A2 (pt) derivados de benzofuralina
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
DE112010004215A5 (de) Hydrostataktor
EP2397480A4 (en) DIAZEPINEDIONEDERIVATE
BRPI1008827A2 (pt) deisobutenizador
BRPI1013844A2 (pt) derivados de piridina-isoxazol
BRPI1014968A2 (pt) subalargador
DE112010002728A5 (de) Turboinhalator
DE112010004249A5 (de) Spindelaktor
BRPI1014454A2 (pt) derivados de isoxazol-pirazol
DE112009005323A5 (de) Hebelarmprüfmaschine
BR112012004964A2 (pt) girocóptero
BRPI1008070A2 (pt) tricianoboratos
DK2387580T3 (da) Deoxyactagardinderivater
EP2401281A4 (en) PYRIMIDINPYRIMIDOINDAZOLDERIVAT
BR112012002810A2 (pt) derivados de n1-acil-5-fluoropirimidinona
BRPI1007369A2 (pt) derivados de di-hidroquinolinona
EP2492266A4 (en) 5-hydroxypyrimidine-4-carboxamide
BRPI1011416A2 (pt) derivados de antraquinova novos
DE112010004865T8 (de) Lamellennassreibkupplung

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/06/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF